Elgan Pharma Ltd.
Clinical trials sponsored by Elgan Pharma Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to help tiniest babies absorb nutrients safely Results expected Jun 2027 (estimated)
-
New drug aims to help tiniest babies absorb nutrients safely
Disease control Recruiting nowThis study tests a drug called ELGN-2112 in 60 very premature infants (born before 26 weeks) and growth-restricted infants (born 26-32 weeks). The goal is to see if the drug is safe compared to a placebo. If it works, it could help these fragile babies absorb nutrients better.
Phase 2 • Sponsor: Elgan Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Could a new drug help tiny babies feed faster?
Disease control Recruiting nowThis study tests a drug called ELGN-2112 in preterm infants born between 26 and 32 weeks who have trouble absorbing food. The goal is to see if the drug helps them reach full feeding sooner compared to a placebo. About 360 babies will take part in this Phase 3 trial.
Phase 3 • Sponsor: Elgan Pharma Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC